BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Merck Sharp & Dohme Ltd. submitted on 29 September 2004 an application for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for FOSAVANCE, through the centralised procedure. After agreement by the CHMP on 25 September 
2003, this medicinal product has been referred to Part B of the Annex to Council Regulation No 
(EEC) 2309/93 of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
I. Hudson 
Co-Rapporteur:  J. Suko 
2. 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 25 July 2002, 26 June 2003 and 
15 December 2004. The Scientific Advice pertained to non-clinical and clinical aspects of the dossier.  
3. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
4. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 29 September 2004.  
The procedure started on 18 October 2004. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on 
23 December 2004. The Co-Rapporteur's first  Assessment  Report  was  circulated to all CHMP 
members on 23 December 2004. 
During the  meeting  on 15 – 17 February 2005, the CHMP agreed on the  consolidated List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 17 February 2005. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 9 March 
2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 25 April 2005. 
During the meeting on 23-26 May 2005, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to FOSAVANCE on 26  May 2005. The applicant provided the letter 
of undertaking on the follow-up measure to be fulfilled post-authorisation on 25 May 2005. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 24 August 2005. 
1/1 

EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
